The FDA is reportedly about to make approving a coronavirus vaccine before the election a lot tougher


The Food and Drug Administration is poised to roll out new, rigorous standards for an emergency approval for a coronavirus vaccine, The Washington Post reports.
The standards, which appear to be an example of the agency's efforts to increase public trust amid the politicization of vaccine development, could be unveiled as soon as this week and are expected to be much tougher than what was used for the controversial emergency clearances of potential COVID-19 treatments hydroxychloroquine and convalescent plasma, per the Post. Manufacturers will be asked to follow vaccine trial participants for at least two months after they receive their second shot, two individuals familiar with situation told the Post on condition of anonymity. The agency will also reportedly be looking for at least five severe COVID-19 cases in the placebo group for each trial, as well as some cases of the disease in older people to see if the vaccine works.
Given the new standards, plus the time it will take companies developing vaccine candidates to apply for an emergency use authorization and for the FDA to review the data, "it's hard to imagine how an EUA could possibly occur before December," Paul Offit, the director of the Vaccine Education Center at Children's Hospital of Philadelphia and FDA vaccine advisory board member, told the Post.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
That will likely allay at least some fears that the White House will try to push a vaccine out before the November election, although there are some people who think the FDA shouldn't grant an EUA for a vaccine at all since there'd still be less safety data required for approval than under normal circumstances. Read more at The Washington Post.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
The Assassin: action-packed caper is 'terrific fun'
The Week Recommends Keeley Hawes stars as a former hitwoman drawn out of retirement for 'one last job'
-
The EPA wants to green-light approval for a twice-banned herbicide
Under the radar Dicamba has been found to harm ecosystems
-
Sudoku medium: July 30, 2025
The Week's daily medium sudoku puzzle
-
Thailand, Cambodia agree to ceasefire in border fight
Speed Read At least 38 people were killed and more than 300,000 displaced in the recent violence
-
Israel 'pauses' Gaza military activity as aid outcry grows
Speed Read The World Health Organization said malnutrition has reached 'alarming levels' in Gaza
-
US and EU reach trade deal
Speed Read Trump's meeting with European Commission President Ursula von der Leyen resulted in a tariff agreement that will avert a transatlantic trade war
-
At least 12 dead in Thai-Cambodian clashes
Speed Read Both countries accused the other of firing first
-
US and Japan strike trade deal
Speed Read Trump signed what he's calling the 'largest deal ever made'
-
28 nations condemn Israel's 'inhumane killing' in Gaza
Speed Read Countries including Australia, France, Japan and the U.K. have released a joint statement condemning Israel's ongoing attacks
-
Israeli gunfire kills dozens at Gaza aid site
Speed Read The U.N. estimates that at least 875 Palestinians have died while trying to access food in recent months
-
Rubio says US brokered end to Syria conflict
Speed Read Syria's defense ministry was targeted in Israeli attacks on the capital